CN108653559A - A kind of hypoglycemic composition and its application - Google Patents
A kind of hypoglycemic composition and its application Download PDFInfo
- Publication number
- CN108653559A CN108653559A CN201810703756.0A CN201810703756A CN108653559A CN 108653559 A CN108653559 A CN 108653559A CN 201810703756 A CN201810703756 A CN 201810703756A CN 108653559 A CN108653559 A CN 108653559A
- Authority
- CN
- China
- Prior art keywords
- ginseng
- blood
- hypoglycemic
- lowering side
- sugar lowering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of hypoglycemic compositions, including the mass ratio of ginseng-astragalus blood-sugar lowering side and melbine, the ginseng-astragalus blood-sugar lowering side and melbine is (2~6.5)：1；The ginseng-astragalus blood-sugar lowering side includes following raw material：Ginsenoside, Schisandra chinensis, Radix Astragali, Chinese yam, glutinous rehmannia, raspberry, Radix Ophiopogonis, Poria cocos, root of Chinese trichosanthes, rhizoma alismatis and the fruit of Chinese wolfberry.The invention also discloses the purposes of the hypoglycemic composition.The application discovery, ginseng-astragalus blood-sugar lowering side and melbine group, which are combined, can generate synergistic effect, compared with single drug using the advantage of having more, can play better blood sugar decreasing effect, more effectively treat diabetes.
Description
Technical field
The invention belongs to biomedicine technical fields, and in particular to a kind of hypoglycemic composition and its application.
Background technology
Diabetes are one group of metabolic diseases characterized by hyperglycemia.Hyperglycemia be then due to defect of insulin secretion or
Its biological effect is impaired, or both have concurrently and cause.Long-standing hyperglycemia when diabetes, cause various tissues, especially eye,
Kidney, heart, blood vessel, the chronic lesion of nerve, dysfunction.With socio-economic development and the improvement of people's living standards, sugar
Urine disease has become common disease, frequently-occurring disease.Studies have shown that crowd's diabetes illness in the big or middle city of China and small towns 20 years old or more
Rate alreadys exceed 10%, it is contemplated that is up to tens of millions of people to China diabetic in 2025.
Diabetes are one of three big difficult and complicated illness of the world, and in decades, countries in the world have carried out long-term and unremitting grind one after another
Study carefully and develops.Reached tens of kinds currently used for Chinese and Western medicine used in clinical treatment, but due to diabetes pathology, etiological study extremely
The breakthrough of modern substance not yet, treatment diabetes increase the stage still in control blood glucose, glucose in urine and prevent comprehensive complication
Conceptual phase.
Invention content
Based on this, a kind of hypoglycemic combination is provided it is an object of the invention to overcome above-mentioned the deficiencies in the prior art place
Object can generate synergistic effect between component, can play better blood sugar decreasing effect.
To achieve the above object, the technical solution adopted by the present invention is：A kind of hypoglycemic composition, including ginseng-astragalus blood-sugar lowering side
And melbine, the mass ratio of the ginseng-astragalus blood-sugar lowering side and melbine is (2~6.5)：1；
The ginseng-astragalus blood-sugar lowering side includes following raw material：Ginsenoside, Schisandra chinensis, Radix Astragali, Chinese yam, glutinous rehmannia, raspberry,
Radix Ophiopogonis, Poria cocos, root of Chinese trichosanthes, rhizoma alismatis and the fruit of Chinese wolfberry.
Ginseng-astragalus blood-sugar lowering side of the present invention is purchased from Guangdong Wannianqing Pharmaceutical Co., Ltd., and product identification is
A14002413893。
Preferably, the mass ratio of the ginseng-astragalus blood-sugar lowering side and melbine is (3~6)：1.
Preferably, the mass ratio of the ginseng-astragalus blood-sugar lowering side and melbine is 4：1.
Present inventor is had found by a large amount of research and analysis, when the mass ratio of ginseng-astragalus blood-sugar lowering side and melbine is
4：When 1, best blood sugar decreasing effect can be obtained.
The present invention also provides purposes of the hypoglycemic composition in being used to prepare hypoglycemic drug.
Hypoglycemic composition of the present invention can be used for preparing hypoglycemic drug.
The present invention also provides a kind of hypoglycemic drugs, including the hypoglycemic composition and pharmaceutically acceptable load
Body.
Preferably, the drug is peroral dosage form.
Preferably, the peroral dosage form includes tablet, granule, capsule, pill and powder agent.
Compared with the existing technology, beneficial effects of the present invention are：Ginseng-astragalus blood-sugar lowering traditional Chinese medicinal components and two in the present composition
Synergistic effect can be generated between first biguanides, compared with single drug using the advantage of having more, can play better blood sugar decreasing effect, more effectively
Treat diabetes in ground.
Specific implementation mode
To better illustrate the object, technical solutions and advantages of the present invention, below in conjunction with specific embodiment to the present invention
It is described further.
Embodiment 1
A kind of embodiment of hypoglycemic composition of the present invention, the hypoglycemic composition include that ginseng-astragalus blood-sugar lowering side and diformazan are double
The mass ratio of guanidine, the ginseng-astragalus blood-sugar lowering side and melbine is 2：1.
Embodiment 2
A kind of embodiment of hypoglycemic composition of the present invention, the hypoglycemic composition include that ginseng-astragalus blood-sugar lowering side and diformazan are double
The mass ratio of guanidine, the ginseng-astragalus blood-sugar lowering side and melbine is 6.5：1.
Embodiment 3
A kind of embodiment of hypoglycemic composition of the present invention, the hypoglycemic composition include that ginseng-astragalus blood-sugar lowering side and diformazan are double
The mass ratio of guanidine, the ginseng-astragalus blood-sugar lowering side and melbine is 3：1.
Embodiment 4
A kind of embodiment of hypoglycemic composition of the present invention, the hypoglycemic composition include that ginseng-astragalus blood-sugar lowering side and diformazan are double
The mass ratio of guanidine, the ginseng-astragalus blood-sugar lowering side and melbine is 4：1.
Embodiment 5
The present embodiment studies the influence to mouse blood sugar and sugar tolerance of hypoglycemic composition of the present invention.
(1) experimental method
It takes SPF grades of db/db mouse, 12 week old, female to carry out adaptability raising after buying, after quarantine, measures every small
Mouse pacifies abdomen blood glucose value (being deprived of food but not water 16hr).Take blood glucose value>16mmol/L animals are included in experiment, according to blood glucose value, animal with
Machine is divided into 7 groups, every group 10.Experiment packet and dosage regimen are as shown in table 1, and each group mouse is administered once daily, and administered volume is
20ml/kg is administered l weeks, and mouse blood sugar value is measured after being administered l hours in the 3rd, 7 day.After last dose measures blood glucose, animal is vertical
2.5g/kg glucose solutions are given, then measure after oral glucose about 30min, 60min, 120min blood glucose value.Animal continues
Administration 3 weeks measures blood glucose in l hours and 2 hours after last 1 administration, and subsequent orbital venous plexus takes whole blood determination HbAle egg
In vain.
1 each group mouse dosage regimen of table
(2) experimental result
The testing result of mouse blood sugar and sugar tolerance is as shown in table 2 after one week of dosing for each group：
The testing result of table 2 mouse blood sugar and sugar tolerance after one week of dosing
With model control group ratio, * P<0.05；**P<0.01.
After administration 3 days, mouse blood glucose value is remarkably decreased compared with model control group in experimental group 1~4, and difference is anticipated with statistics
Justice.After administration 7 days, each group mouse blood sugar value is remarkably decreased compared with model control group, but experimental group 1~4 reduces the effect of blood glucose
Better than control group 1~2.To animal pattern sugar dosis tolerata, experimental group 1~4 and control group 2 show preferable raising animal sugar tolerance
Effect, but experimental group 1~4 improve animal sugar tolerance effect be better than control group 2.Illustrate (to be administered alone ginseng stilbene with control group 1
Blood sugar-reduction formula) it is compared with control group 2 (being administered alone melbine), experimental group 1~4 (composition in administration Examples 1 to 4) reduces
Animal blood glucose and the effect for improving animal sugar tolerance are more preferable, and especially effect is most for experimental group 4 (composition in administration embodiment 4)
It is good.The above results can generate synergistic effect after showing ginseng-astragalus blood-sugar lowering side and combination with metformin, can preferably play reduction blood glucose
With the effect for improving sugar tolerance.
The testing result of mouse blood sugar is as shown in table 3 after each group is administered 3 weeks：
Mouse blood sugar testing result after table 3 is administered 3 weeks
| Group | Blood glucose before administration | Blood glucose value after last dose 1 hour | Blood glucose value after last dose 2 hours |
| Model control group | 19.30±6.68 | 22.86±5.49 | 22.53±4.70 |
| Control group 1 | 19.19±6.25 | 16.20±3.84* | 13.72±2.58** |
| Control group 2 | 18.14±3.62 | 16.50±3.63* | 14.26±3.09** |
| Experimental group 1 | 18.14±6.03 | 12.23±5.80** | 11.43±3.03** |
| Experimental group 2 | 17.51±4.67 | 13.24±3.61** | 12.61±2.86** |
| Experimental group 3 | 18.25±4.80 | 12.57±3.95** | 11.63±3.08** |
| Experimental group 4 | 17.93±4.56 | 11.28±4.02** | 10.85±3.22** |
With model control group ratio, * P<0.05；**P<0.01.
After being administered 3 weeks, 1 hour and 2 hours after the last administration, each group mouse blood sugar value was notable compared with animal pattern control group
Decline, but experimental group 1~4 (composition in administration Examples 1 to 4) hypoglycemic effect (is administered alone ginseng stilbene better than control group 1
Blood sugar-reduction formula) and control group 2 (being administered alone melbine), and experimental group 4 (composition in administration embodiment 4) effect is best.
The testing result of mouse glycosylated hemoglobin is as shown in table 4 after each group is administered 3 weeks：
Mouse glycosylated hemoglobin testing result after table 4 is administered 3 weeks
| Group | GHb(A/10gHb) |
| Model control group | 73.40±28.45 |
| Control group 1 | 50.53±26.26* |
| Control group 2 | 42.03±29.67* |
| Experimental group 1 | 22.75±12.52** |
| Experimental group 2 | 27.50±13.81** |
| Experimental group 3 | 25.02±10.85** |
| Experimental group 4 | 20.13±11.15** |
With model control group ratio, * P<0.05；**P<0.01.
After being administered 3 weeks, orbital venous plexus takes whole blood determination glycosylated hemoglobin.Glycosylated hemoglobin is red blood cell in blood
The combination generation glycosylated hemoglobin of the product that interior hemoglobin is combined with blood glucose, blood glucose and hemoglobin is can not be converse
It answers, and is proportionate with blood sugar concentration.It is in table 4 the result shows that, each group animal glycosylated hemoglobin is aobvious compared with model control group
It writes and declines, but experimental group 1~4 (composition in administration Examples 1 to 4) reduces the effect of animal glycosylated hemoglobin better than control
1 (being administered alone ginseng-astragalus blood-sugar lowering side) of group and control group 2 (being administered alone melbine).And (group in embodiment 4 is administered in experimental group 4
Close object) effect is best.Synergistic effect can be generated after illustrating ginseng-astragalus blood-sugar lowering side and combination with metformin, can preferably play reduction sugar
Change the effect of hemoglobin.
Finally, it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention rather than is protected to the present invention
The limitation of range is protected, although being explained in detail to the present invention with reference to preferred embodiment, those skilled in the art should
Understand, technical scheme of the present invention can be modified or replaced equivalently, without departing from the essence of technical solution of the present invention
And range.
Claims (7)
1. a kind of hypoglycemic composition, which is characterized in that include ginseng-astragalus blood-sugar lowering side and melbine, the ginseng-astragalus blood-sugar lowering side and two
The mass ratio of first biguanides is (2~6.5)：1；
The ginseng-astragalus blood-sugar lowering side includes following raw material：Ginsenoside, Schisandra chinensis, Radix Astragali, Chinese yam, glutinous rehmannia, raspberry, wheat
Winter, Poria cocos, root of Chinese trichosanthes, rhizoma alismatis and the fruit of Chinese wolfberry.
2. hypoglycemic composition according to claim 1, which is characterized in that the matter of the ginseng-astragalus blood-sugar lowering side and melbine
Amount is than being (3~6)：1.
3. hypoglycemic composition according to claim 1, which is characterized in that the matter of the ginseng-astragalus blood-sugar lowering side and melbine
Amount is than being 4：1.
4. according to purposes of the claims 1 to 3 any one of them hypoglycemic composition in being used to prepare hypoglycemic drug.
5. a kind of hypoglycemic drug, which is characterized in that include claims 1 to 3 any one of them hypoglycemic composition and medicine
The acceptable carrier of object.
6. hypoglycemic drug according to claim 5, which is characterized in that the drug is peroral dosage form.
7. hypoglycemic drug according to claim 6, which is characterized in that the peroral dosage form includes tablet, granule, glue
Wafer, pill and powder agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810703756.0A CN108653559A (en) | 2018-06-29 | 2018-06-29 | A kind of hypoglycemic composition and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810703756.0A CN108653559A (en) | 2018-06-29 | 2018-06-29 | A kind of hypoglycemic composition and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108653559A true CN108653559A (en) | 2018-10-16 |
Family
ID=63772665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810703756.0A Pending CN108653559A (en) | 2018-06-29 | 2018-06-29 | A kind of hypoglycemic composition and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108653559A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110251633A (en) * | 2019-03-12 | 2019-09-20 | 新乡医学院第一附属医院(河南省结核病医院) | A kind of pharmaceutical composition and preparation method thereof for treating Diabetes Complicated with Pulmonary Tuberculosis disease |
-
2018
- 2018-06-29 CN CN201810703756.0A patent/CN108653559A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110251633A (en) * | 2019-03-12 | 2019-09-20 | 新乡医学院第一附属医院(河南省结核病医院) | A kind of pharmaceutical composition and preparation method thereof for treating Diabetes Complicated with Pulmonary Tuberculosis disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103285231B (en) | Medicine composition for diabetes adjunctive therapy and preparation method thereof | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN104000197B (en) | A kind of health products or pharmaceutical composition and its production and use of fatigue-relieving | |
| CN103394045B (en) | Chinese medicine composition and preparation method and application thereof | |
| CN1299742C (en) | Medicine for treating diabetes, and its prepn. method | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN106924374A (en) | A kind of composition and preparation method thereof and the application in hypoglycemic and/or reducing blood lipid product is prepared | |
| CN104083640B (en) | Traditional Chinese medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN108653559A (en) | A kind of hypoglycemic composition and its application | |
| CN103655599A (en) | Polysaccharide composition, application and medicinal preparation containing same | |
| CN100423754C (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
| CN105250989A (en) | Donkey-hide glue small peptide composition for resisting fatigue | |
| CN108066350B (en) | Application of phillyrin, phillyrin derivatives, and phillyrin-phillygenin composition in preparation of medicines for preventing and treating senile dementia | |
| CN100493522C (en) | Medicinal composition of oxymatrine and polysaccharide | |
| CN103768579A (en) | Traditional Chinese medicine for reducing blood sugar and preparation method thereof | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN104352748A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN101293059B (en) | Compound Chinese medicine for treating diabetes | |
| CN1557378A (en) | Medicine for treating diabetes | |
| CN100340271C (en) | Hypoglycemic medicine for treating diabetes and its prepn process | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN103599259A (en) | Dai medicine extract with hypoglycemic effect, preparation and application thereof | |
| CN108567867A (en) | A kind of Chinese medicine composition that treating chronic nephritis and its application | |
| CN101491581A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN102225082A (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181016 |
|
| RJ01 | Rejection of invention patent application after publication |